Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

NSCLC Videos

Edward Garon, MD, MS
Conference Coverage
05/15/2024
Edward Garon, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.
At the Great Debates and Updates...
05/15/2024
Oncology
Corey Langer, MD
Conference Coverage
05/14/2024
Corey Langer, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, argued that continuing pemetrexed maintenance therapy is advantageous for patients treated with the KEYNOTE-189 regimen.
At the Great Debates and Updates...
05/14/2024
Oncology
Charles Simone, MD
Conference Coverage
04/27/2024

Featuring Charles Simone, MD

Featuring Charles Simone, MD
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
At the Great Debates and Updates...
04/27/2024
Oncology
Joshua Sabari, MD
Videos
04/02/2024

Featuring Joshua Sabari, MD

Featuring Joshua Sabari, MD
Joshua Sabari, MD, discussed exploratory analysis results from the phase 3 MARIPOSA study evaluating the impact of amivantamab dose interruptions, as presented at the European Lung Cancer Congress 2024.
Joshua Sabari, MD, discussed exploratory analysis results from the phase 3 MARIPOSA study evaluating the impact of amivantamab dose interruptions, as presented at the European Lung Cancer Congress 2024.
Joshua Sabari, MD, discussed...
04/02/2024
Oncology
Alex Spira, MD, PhD, FACP
Videos
04/02/2024

Featuring Alex Spira, MD, PhD, FACP

Featuring Alex Spira, MD, PhD, FACP ...
Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.
Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.
Alexander Spira, MD, PhD, FACP,...
04/02/2024
Oncology
Joshua Sabari, MD
Videos
03/25/2024

Featuring Joshua Sabari, MD

Featuring Joshua Sabari, MD
Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...
Joshua Sabari, MD, discussed post-progression secondary end points from the phase 3 PAPILLON trial evaluating amivantamab plus chemotherapy among patients with advanced EGFR-mutated non-small cell lung cancer, as presented at the European...
Joshua Sabari, MD, discussed...
03/25/2024
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
11/06/2023
Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.
Christian Rolfo, MD, PhD, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York, discusses results from the phase 2 VISION trial.
Christian Rolfo, MD, PhD, Icahn...
11/06/2023
Oncology
Patrick Forde, MD
Videos
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Patrick Forde, MD, debated in favor of adjuvant immunotherapy in resectable non-small cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology
Lyudmila Bazhenova, MD
Videos
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.
At the Great Debates & Updates...
09/26/2023
Oncology
Natasha Leighl, MD
Videos
09/26/2023
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, FRCPC, FASCO, discussed the primacy of front-line checkpoint inhibitors in non-small cell lung cancer.
At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Natasha Leighl, MD, FRCPC, FASCO, discussed the primacy of front-line checkpoint inhibitors in non-small cell lung cancer.
At the Great Debates & Updates...
09/26/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement